Distinguishing novel EGFR mutations that are clinically relevant from those that are functionally silent or artefacts is clearly important, particularly as diverse responses to EGFR tyrosine kinase inhibitor (TKI) therapy of patients with NSCLC harbouring uncommon EGFR mutations were recently reported [42]. Here, EGFR is linked to non-small cell lung carcinoma.